Skandinaviska Enskilda Banken AB publ Purchases 62,312 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Skandinaviska Enskilda Banken AB publ increased its stake in Thermo Fisher Scientific Inc. by 35.7%, purchasing an additional 62,312 shares, resulting in a total ownership of approximately 236,919 shares valued at about $117,891,000.
• Several analysts have adjusted their price targets for Thermo Fisher Scientific, with a consensus rating of "Moderate Buy" and an average price target of $593.00.
• Thermo Fisher Scientific has announced a quarterly dividend of $0.43 per share, representing an annualized dividend of $1.72 and a dividend yield of 0.36%.

Skandinaviska Enskilda Banken AB publ boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 35.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 236,919 shares of the medical research company's stock after purchasing an additional 62,312 shares during the period. Thermo Fisher Scientific comprises 0.6% of Skandinaviska Enskilda Banken AB publ's holdings, making the stock its 29th largest position. Skandinaviska Enskilda Banken AB publ owned approximately 0.06% of Thermo Fisher Scientific worth $117,891,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the last quarter. Port Capital LLC lifted its stake in Thermo Fisher Scientific by 1.6% in the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after purchasing an additional 22 shares during the last quarter. Clark Capital Management Group Inc. lifted its stake in Thermo Fisher Scientific by 0.5% in the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock valued at $2,312,000 after purchasing an additional 23 shares during the last quarter. Monograph Wealth Advisors LLC lifted its stake in Thermo Fisher Scientific by 0.3% in the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock valued at $4,507,000 after purchasing an additional 23 shares during the last quarter. Finally, Intergy Private Wealth LLC lifted its stake in Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after purchasing an additional 23 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on TMO shares. Raymond James Financial restated an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Robert W. Baird raised their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday. Finally, HSBC reiterated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president owned 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $475.16 on Friday. The company has a market capitalization of $179.37 billion, a P/E ratio of 27.48, a P/E/G ratio of 2.25 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.38. The business has a fifty day simple moving average of $412.43 and a two-hundred day simple moving average of $470.68.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the company posted $5.37 EPS. The company's revenue for the quarter was up 2.9% on a year-over-year basis. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.